Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin detemir - Novo Nordisk

Drug Profile

Insulin detemir - Novo Nordisk

Alternative Names: Levemir; Levemir FlexPen; Levemir FlexTouch; LysB29-tetradecanoyl des-(B30) human insulin; NN 304

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 27 Sep 2021 BIOCORP and Novo Nordisk enter into a partnership agreement for the use of Mallya technology for FlexTouch pen
  • 15 Apr 2021 Discontinued- Phase-III for Type 1 diabetes mellitus (In adolescents, In children, In infants) in Russia, South Africa, Macedonia, Japan (SC) (NCT01513473)
  • 15 Apr 2021 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents, In children) in Brazil, India, Israel, Malaysia, Mexico, Russia, South Korea, Taiwan, Turkey (SC) (NCT02131272)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top